TICKERNERD
Menu
ANIKANIKHealthcare · Drug Manufacturers - Specialty & Generic

ANIK Stock Forecast: Anika Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$20
+2.14% on the day

The 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $23 — +17.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$255.9M
Ticker Nerd rank
100 / 100
Median analyst target
$23
Analysts covering
2
Revenue$32.6M+15.6% y/y
Operating income$3.0M
Net income$3.3M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.7%
1M
−6.2%
YTD
+103.2%
1Y
+114.9%
From 52W high
−11.3%
From 52W low
+116.5%
$9
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
95
Growth
95
Value
91
Momentum
90
Issuance
81
Quality
73
Volatility
65
Size
64
Accruals
60

Revisions (95): Analysts have, on balance, been raising their forecasts.

Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANIK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26ANIKHigh $23Median $23Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $23Median $23High $23

The green dot is the last close — the median target sits +17.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Sept 2026B. Riley SecuritiesAssumesBuy$21 → $23
30 July 2026B. Riley SecuritiesMaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$18 → $21
27 Feb 2026Barrington ResearchMaintainsOutperform$16 → $17
27 Feb 2026Barrington ResearchMaintainsOutperform—
9 Jan 2026Barrington ResearchMaintainsOutperform—
6 Nov 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
31 July 2025Barrington ResearchMaintainsOutperform—
12 May 2025Barrington ResearchMaintainsOutperform—
13 Mar 2025Barrington ResearchMaintainsOutperform—
1 Nov 2024Barrington ResearchMaintainsOutperform—
22 Oct 2024Barrington ResearchMaintainsOutperform—
9 Aug 2024Barrington ResearchMaintainsOutperform—
29 May 2024Stephens & Co.ReiteratesEqual-Weight—
9 May 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Stephens & Co.ReiteratesEqual-Weight—
3 Jan 2024Barrington ResearchMaintainsOutperform—
3 Nov 2023Barrington ResearchMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANIK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Anika Therapeutics, Inc. returned +114.9% against +17.4% for the S&P 500, dividends included.

ANIK vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26ANIKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+156.1%
Analysts raising
0
Analysts cutting
1
Fundamentals

Anika Therapeutics, Inc. (ANIK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−25.6×

Cheaper than 97% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
79.8×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 63% of US stocks

Earnings growth (YoY)
15.6%

Higher than 53% of US stocks

Gross margin
65.1%

Higher than 78% of US stocks

Operating margin
11.4%

Higher than 66% of US stocks

Net margin
−3.1%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−2.2%

Higher than 42% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anika Therapeutics, Inc. (ANIK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anika Therapeutics, Inc. has a market value of $255.9M and an enterprise value of $242.7M.

  • Revenue in the twelve months to 30 June 2026: $120.7M. The latest quarter grew 15.6% year on year.

  • Net income over the same four quarters: −$3.8M, a −3.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.27.

  • Free cash flow in the twelve months to 30 June 2026: $562K.

  • Anika Therapeutics, Inc. spent $15.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 13.3M.

  • Trailing P/E: −25.6×; forward P/E: 20.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Anika Therapeutics, Inc. employs 235 people — $513K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ANIK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ANIKAnika Therapeutics, Inc.$255.9M
100
LFCRLifecore Biomedical, Inc.$244.5M
2
SIGASIGA Technologies, Inc.$235.7M
44
AKBAAkebia Therapeutics, Inc.$235.3M
72
BIOABioAge Labs, Inc.$279.1M
37
ACBAurora Cannabis, Inc.$297.3M
59
EBSEmergent BioSolutions, Inc.$359.8M
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIK news & analysis

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Zacks Investment Research · 25 Sept 2026neutral

A Zacks Investment Research piece compares the year-to-date stock performance of Anika Therapeutics (ANIK) and Concentra Group (CON) relative to their medical sector. The article evaluates how each company has fared against its industry peers so far this year.

Why it matters — This gives Anika watchers a direct performance comparison against a peer and the broader medical sector over the year.

Best Momentum Stocks to Buy for August 26th

Zacks Investment Research · 26 Aug 2026positive

On August 26th, 2026, Anika Therapeutics, Inc. (ANIK) was included in Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) momentum stocks, alongside BTSG and OPHC.

Why it matters — For ANIK watchers, being named to Zacks' top momentum stock list is a notable external validation of the company's current market standing.

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlighted Anika Therapeutics (ANIK) as a solid choice for shorter-term investors looking to capitalize on recent price trends, noting it passed the firm's shorter-term trading strategy-based screen.

Why it matters — The mention indicates that Anika's recent price trend, combined with its fundamental soundness, is being recognized by a stock-research screen.

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

Zacks Investment Research · 21 Aug 2026positive

Anika Therapeutics' stock has risen 43.4% over the past three months, driven by strong sales momentum and raised 2026 guidance. The company's pipeline is advancing with Cingal and Hyalofast, which have bolstered investor confidence.

Why it matters — ANIK watchers would care because the stock's significant gain, raised guidance, and pipeline progress signal strengthening company performance and growth prospects.

5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns

Zacks Investment Research · 19 Aug 2026positive

Zacks Investment Research highlighted five stocks showing strong recent price gains and earnings growth amid a market rally, including Anika Therapeutics (ANIK) alongside EDRY, OPHC, FET, and NESR.

Why it matters — This item signals that ANIK is being recognized for recent price strength and earnings growth, which may draw attention from investors tracking the stock.

FAQ

Frequently asked questions about ANIK stock

What is the ANIK stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $23 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIK stock a buy right now?

Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 100 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIK?

As at 6 Oct 2026, Anika Therapeutics, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).

Will ANIK stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +17.8% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 100 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIK stock forecast for 2030?

No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $23 over the next 12 months.

How has ANIK stock performed over the past year?

Anika Therapeutics, Inc. returned +114.9% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anika Therapeutics, Inc. do?

Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics.

What is the latest news on ANIK?

The most recent item we track (Zacks Investment Research, 25 Sept 2026): "Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?". A Zacks Investment Research piece compares the year-to-date stock performance of Anika Therapeutics (ANIK) and Concentra Group (CON) relative to their medical sector. The article evaluates how each company has fared against its industry peers so far this year.

Company

About Anika Therapeutics, Inc.

Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics. The company develops, manufactures, and commercializes hyaluronic acid-based products used in osteoarthritis pain management, regenerative medicine, sports medicine, and soft tissue repair. Its portfolio includes injectable therapies and orthopedic solutions designed to support mobility, tissue healing, and minimally invasive care for patients with degenerative joint conditions and musculoskeletal injuries. Anika Therapeutics serves healthcare professionals and clinical settings across the United States, Europe, and other international markets, with products used in orthopedics and related surgical applications. Headquartered in Bedford, Massachusetts, Anika Therapeutics Inc. plays a specialized role in the musculoskeletal care market by offering therapies and biomaterials that address joint health, cartilage repair, and recovery support.

CEO Mr. Stephen D. Griffin · 235 employees · United States · https://www.anika.com